CS
NVAX icon

Candriam SCA’s Novavax NVAX Stock Holding History

Candriam SCA’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43,894
Closed -$799K – 885
2022
Q3 		$799K Sell
43,894
-91,000
-67% -$3.94M 0.01% 758
2022
Q2 		$6.94M Buy
134,894
+129,937
+2,621% +$6.73M 0.06% 280
2022
Q1 		$1.6M Sell
4,957
-67,978
-93% -$6.06M 0.01% 590
2021
Q4 		$10.4M Sell
72,935
-42,844
-37% -$7.36M 0.07% 262
2021
Q3 		$24M Sell
115,779
-7,544
-6% -$1.66M 0.16% 146
2021
Q2 		$26.2M Buy
123,323
+50,774
+70% +$9.3M 0.18% 138
2021
Q1 		$7.77M Hold
72,549
– – 0.06% 295
2020
Q4 		$8.09M Buy
72,549
+23,974
+49% +$2.55M 0.06% 303
2020
Q3 		$5.26M Buy
+48,575
New +$5.92M 0.05% 349
2016
Q3 		– Sell
-11,636
Closed -$1.69M – 676
2016
Q2 		$1.69M Buy
+11,636
New +$1.33M 0.04% 342
2015
Q4 		– Sell
-11,436
Closed -$1.62M – 615
2015
Q3 		$1.62M Buy
+11,436
New +$2.56M 0.04% 370

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIG
Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Candriam SCA's NVAX Position: Q4 2022 in Review

Candriam SCA sold out of Novavax (NVAX) in Q4 2022, closing a stake of 43,894 shares — an estimated $799K sold.

Candriam SCA first reported a position in NVAX in Q3 2015 and held it in 11 quarters. The position peaked at $26.2M in Q2 2021. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

  • Candriam SCA reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
  • Candriam SCA sold 43,894 Novavax shares in Q4 2022, an estimated $799K.
  • Candriam SCA first reported a position in Novavax in Q3 2015 and held it in 11 quarters.
  • Candriam SCA's Novavax position peaked at $26.2M in Q2 2021.
  • 252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.